ONE WEEK THERAPY WITH ORAL TERBINAFINE IN CASES OF TINEA CRURIS/CORPORIS
AbstractWe conducted a study on 27 patients (17 males, 10 females) to evaluate the efficacy of oral Terbinafine on a short term basis. All the patients had clinical and mycologically proven tinea cruris I corporis. Each patient was given 250 mg Terbinafine (Lamisil) after meals, once daily for one week. Patients were followed up for 6 weeks after completion of treatment. Patients were assessed clinically and mycologically at the end of treatment and the end of the follow up period. The signs and symptoms of the disease had almost disappeared at the end of the follow up period. Mycological investigations were negative in all patients at this time, except for one. As reported in other studies, our results show that one-week oral therapy with 250 mg/day of Terbinafine is effective and cheap for the treatment of tinea corporis/cruris
Farag A. One-week therapy with oral terbinafine in
cases of Tinea Cruris/Corporis. BJD, 1994, 131: 684-
Ryder NS. Specific inhibition of fungal sterol
biosynthesis by SF 86-327, a new allylamine
antimycotic agent. Antimic Agents Chemother, 1985;
Ryder NS. The mechanism of action of terbinafine.
Clin Exp. Dermatol, 1989; 14: 98- 100.
Ryder NS. Terbinafine: mode of action and properties
of the squalene episodes’ inhibition. Br J Dermatol,
; 126(Suppl. 39): 2-7.
Tones TC. Treatment of dermatomycoses with
topically applied gailylamines: naftifine and
terbinafine. J Dermatol Treat, 1990; l (Suppl 2): 29-
Aergemann J, Zehender H, Sones T & Maibach 1.
Terbinafine levels in serum, stratum corneum, dermis
epidermis (without stratum corneum), hair, sebum
and eccrine sweat. Acta Derma Venereol (Stock),
; 71: 332-36.
Villars VV & Jones TC. Special features of the
clinical use of oral terbinafine in the treatment of
fungal diseases. Br J Dermatol, 1992; 126 (Suppl.
Sanabria JA, Bonifza A & Saul A. Terbinafine
enaltratameinto de micosis superficial. Dermatology
(Mexico), 1990; 34: 189-98.
Leenutaphong V, Leowatttana W, Boonchai W, et al.
A randomized double blind comparative study of
terbinafine is griseofulum in tinea corporis and tinea
cruris dermatological treatments: preliminary
investigations in the Asia Pacific Region
proceedings, Asia-Pacific Dermatology symposium,
New York (NY, U.S.A.), 15 June 1992. (Evans EGU,
Jafary MH, eds) (International Congress and
symposium series, No. 197) London: Royal Society
of Medicine Services Ltd, 1992; 11- 15.
Frederickson T. Treatment of dermatomycoses with
topical tioconazole and miconazole. Dermatological,
; 166(Suppl. 1): 14-19.
White JE, Perkins PJ & Evans EGV. Successful 2-
week treatment with terbinafine (lamisil) for
moccasin tinea pedis and tinea manum. Br J
Dermatol, 1991: 125: 260-62.
Shear NH, Villars VV & Masolais C. Terbinafine: an
oral and topical antifungal agent. Clin Dermatol,
; 9: 487-95.
Jacobs PH. Treatment of fungal skin infection: state
of the art. J Am Acad Dermatol, 1990; 23: 549-51.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.